Boothbay Fund Management’s UroGen Pharma URGN Stock Holding History

Boothbay Fund Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,075	Closed	-$121K	–	2317
2023 Q1	$121K	Buy	13,075 +1,936	+17%	+$17.8K	﹤0.01%	1875
2022 Q4	$98.8K	Buy	+11,139	New	+$105K	﹤0.01%	1791

Other funds holding URGN

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Boothbay Fund Management's URGN Position: Q2 2023 in Review

Boothbay Fund Management sold out of UroGen Pharma (URGN) in Q2 2023, closing a stake of 13,075 shares — an estimated $121K sold.

Boothbay Fund Management first reported a position in URGN in Q4 2022 and held it in 2 quarters. The position peaked at $121K in Q1 2023. 85 funds tracked by Wall St. Rank hold URGN as of Q2 2023.

Boothbay Fund Management reported no remaining UroGen Pharma position as of Q2 2023 after selling out during the quarter.
Boothbay Fund Management sold 13,075 UroGen Pharma shares in Q2 2023, an estimated $121K.
Boothbay Fund Management first reported a position in UroGen Pharma in Q4 2022 and held it in 2 quarters.
Boothbay Fund Management's UroGen Pharma position peaked at $121K in Q1 2023.
85 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.